SiRNA-targeting transforming growth factor-β type i receptor reduces wound scarring and extracellular matrix deposition of scar tissue

Journal of Investigative Dermatology

Volumn 134, Issue 7, 2014, Pages 2016-2025

  Wang, Yi Wen ^a,b   Liou, Nien Hsien ^a   Cherng, Juin Hong ^a   Chang, Shu Jen ^c   Ma, Kuo Hsing ^a   Fu, Earl ^a   Liu, Jiang Chuan ^a   Dai, Niann Tzyy ^b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EXPERIMENTAL RABBIT; EXTRACELLULAR MATRIX; FIBROBLAST; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; HYPERTROPHIC SCAR; IMMUNOFLUORESCENCE; NONHUMAN; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RATING SCALE; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VANCOUVER SCAR SCALE; VISUAL ANALOG SCALE; WESTERN BLOTTING; WOUND HEALING;

ANIMALS; CELL PROLIFERATION; CICATRIX, HYPERTROPHIC; COLLAGEN TYPE I; COLLAGEN TYPE III; CONNECTIVE TISSUE GROWTH FACTOR; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBRONECTINS; GENETIC THERAPY; GRANULATION TISSUE; HUMANS; PRIMARY CELL CULTURE; PROTEIN-SERINE-THREONINE KINASES; RABBITS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, SMALL INTERFERING; WOUND HEALING;

EID: 84902547859     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.84     Document Type: Article

References (47)

1. Bayat A, McGrouther DA, Ferguson MW (2003) Skin scarring. BMJ 326: 88-92
2. Boys ML, Bian F, Kramer JB et al. (2012) Discovery of a series of 2-(1Hpyrazol- 1-yl)pyridines as ALK5 inhibitors with potential utility in the prevention of dermal scarring. Bioorg Med Chem Lett 22: 3392-7
3. Brown RL, Ormsby I, Doetschman TC et al. (1995) Wound healing in the transforming growth Factor-b-deficient mouse. Wound Repair Regen 3: 25-36
4. Burger A, Wagner C, Viedt C et al. (1998) Fibronectin synthesis by human tubular epithelial cells in culture: effects of PDGF and TGF-beta on synthesis and splicing. Kidney Int 54: 407-15
5. Chin GS, Liu W, Peled Z et al. (2001) Differential expression of transforming growth Factor-b receptors I and II and activation of Smad 3 in keloid fibroblasts. Plast Reconstr Surg 108: 423-9
6. Chu Y, Guo F, Li Y et al. (2008) A novel truncated TGF-beta receptor II downregulates collagen synthesis and TGF-beta I secretion of keloid fibroblasts. Connect Tissue Res 49: 92-8
7. Cordeiro MF, Gay JA, Khaw PT (1999) Human anti-transforming growth Factor-b2 antibody: a new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci 40: 2225-34
8. Cordeiro MF, Mead A, Ali RR et al. (2003) Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome. Gene Ther 10: 59-71
9. Cutroneo KR (2007) TGF-beta-induced fibrosis and SMAD signaling: oligo decoys as natural therapeutics for inhibition of tissue fibrosis and scarring. Wound Repair Regen 15(Suppl 1):S54-60 (Pubitemid 47301675)
10. de Gouville AC, Boullay V, Krysa G et al. (2005) Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamineinduced liver fibrosis. Br J Pharmacol 145: 166-77
11. Denton CP, Lindahl GE, Khan K et al. (2005) Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II transforming growth factor-{beta} receptor (T{beta}RII{delta}k). J Biol Chem 280: 16053-65
12. Dominska M, Dykxhoorn DM (2010) Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci 123: 1183-9
13. Edmondson SR, Thumiger SP, Werther GA et al. (2003) Epidermal homeostasis: the role of the growth hormone and insulin-like growth factor systems. Endocr Rev 24: 737-64
14. Ellis LR, Warner DR, Greene RM et al. (2003) Interaction of Smads with collagen types I, III, and V. Biochem Biophys Res Commun 310: 1117-23
15. Fearmonti R, Bond J, Erdmann D et al. (2010) A review of scar scales and scar measuring devices. Eplasty 10:e43
16. Gauglitz GG, Korting HC, Pavicic T et al. (2011) Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med 17: 113-25
17. Goumans MJ, Valdimarsdottir G, Itoh S et al. (2003) Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell 12: 817-28
18. Hinz B, Celetta G, Tomasek JJ et al. (2001) Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol Biol Cell 12: 2730-41
19. Kim YW, Kim YK, Lee JY et al. (2008) Pharmacokinetics and tissue distribution of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2- yl)methyl) benzamide; a novel ALK5 inhibitor and a potential anti-fibrosis drug. Xenobiotica 38: 325-39
20. Kloeters O, Tandara A, Mustoe TA (2007) Hypertrophic scar model in the rabbit ear: a reproducible model for studying scar tissue behavior with new observations on silicone gel sheeting for scar reduction. Wound Repair Regen 15(Suppl 1):S40-5 (Pubitemid 47301673)
21. Leask A, Abraham DJ (2004) TGF-beta signaling and the fibrotic response. FASEB J 18: 816-27
22. Leask A, Holmes A, Black CM et al. (2003) Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth Factor-b 2 in fibroblasts. J Biol Chem 278: 13008-15
23. Lee JW, Tutela JP, Zoumalan RA et al. (2010) Inhibition of Smad3 expression in radiation-induced fibrosis using a novel method for topical transcutaneous gene therapy. Arch Otolaryngol Head Neck Surg 136: 714-9
24. Lu L, Saulis AS, Liu WR et al. (2005) The temporal effects of anti-TGF-beta1, 2, and 3 monoclonal antibody on wound healing and hypertrophic scar formation. J Am Coll Surg 201: 391-7
25. Mead AL, Wong TT, Cordeiro MF et al. (2003) Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci 44: 3394-401
26. Morris DE, Wu L, Zhao LL et al. (1997) Acute and chronic animal models for excessive dermal scarring: quantitative studies. Plast Reconstr Surg 100: 674-81
27. Nakamura H, Siddiqui SS, Shen X et al. (2004) RNA interference targeting transforming growth Factor-b type II receptor suppresses ocular inflammation and fibrosis. Mol Vis 10: 703-11
28. Pannu J, Gore-Hyer E, Yamanaka M et al. (2004) An increased transforming growth factor beta receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinasedeficient transforming growth factor beta receptor type II in scleroderma. Arthritis Rheum 50: 1566-77
29. Pohlers D, Brenmoehl J, Loffler I et al. (2009) TGF-beta and fibrosis in different organs -molecular pathway imprints. Biochim Biophys Acta 1792: 746-56
30. Profyris C, Tziotzios C, Do Vale I (2012) Cutaneous scarring: pathophysiology, molecular mechanisms, and scar reduction therapeutics Part I. The molecular basis of scar formation. J Am Acad Dermatol 66: 1-1
31. Reid RR, Roy N, Mogford JE et al. (2007) Reduction of hypertrophic scar via retroviral delivery of a dominant negative TGF-beta receptor II. J Plast Reconstr Aesthet Surg 60: 64-72
32. Rnjak J, Li Z, Maitz PK et al. (2009) Primary human dermal fibroblast interactions with open weave three-dimensional scaffolds prepared from synthetic human elastin. Biomaterials 30: 6469-77
33. Sarrazy V, Billet F, Micallef L et al. (2011) Mechanisms of pathological scarring: role of myofibroblasts and current developments. Wound Repair Regen 19(Suppl 1):s10-5
34. Schmid P, Itin P, Cherry G et al. (1998) Enhanced expression of transforming growth Factor-b type I and type II receptors in wound granulation tissue and hypertrophic scar. Am J Pathol 152: 485-93
35. Sekiguchi K, Tian Q, Ishiyama M et al. (2007) Inhibition of PPAR-alpha activity in mice with cardiac-restricted expression of tumor necrosis factor: potential role of TGF-beta/Smad3. Am J Physiol Heart Circ Physiol 292:H1443-51
36. Shah M, Foreman DM, Ferguson MW (1994) Neutralising antibody to TGFbeta 1,2 reduces cutaneous scarring in adult rodents. J Cell Sci 107 (Pt 5): 1137-57
37. Shen N, Lin H, Wu T et al. (2013) Inhibition of TGF-beta1-receptor posttranslational core fucosylation attenuates rat renal interstitial fibrosis. Kidney Int 84: 64-77
38. Shi-Wen X, Rodriguez-Pascual F, Lamas S et al. (2006) Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Mol Cell Biol 26: 5518-27
39. Sonnylal S, Denton CP, Zheng B et al. (2007) Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum 56: 334-44
40. Takasao N, Tsuji-Naito K, Ishikura S et al. (2012) Cinnamon extract promotes type I collagen biosynthesis via activation of IGF-I signaling in human dermal fibroblasts. J Agric Food Chem 60: 1193-200
41. Tsujita-Kyutoku M, Uehara N, Matsuoka Y et al. (2005) Comparison of transforming growth Factor-b/Smad signaling between normal dermal fibroblasts and fibroblasts derived from central and peripheral areas of keloid lesions. In Vivo 19: 959-63
42. Vogt J, Traynor R, Sapkota GP (2011) The specificities of small molecule inhibitors of the TGFss and BMP pathways. Cell Signal 23: 1831-42
43. Wang J, Lu Z, Wientjes MG et al. (2010) Delivery of siRNA therapeutics: barriers and carriers. AAPS J 12: 492-503
44. Wang L, Zheng J, Bai X et al. (2009) ADAMTS-7 mediates vascular smooth muscle cell migration and neointima formation in balloon-injured rat arteries. Circ Res 104: 688-98
45. Wang Z, Gao Z, Shi Y et al. (2007) Inhibition of Smad3 expression decreases collagen synthesis in keloid disease fibroblasts. J Plast Reconstr Aesthet Surg 60: 1193-9
46. Wilson TR, McLaughlin KM, McEwan M et al. (2007) c-FLIP: a key regulator of colorectal cancer cell death. Cancer Res 67: 5754-62
47. Zhang Z, Garron TM, Li XJ et al. (2009) Recombinant human decorin inhibits TGF-beta1-induced contraction of collagen lattice by hypertrophic scar fibroblasts. Burns 35: 527-37